Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
NCT04634760
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Japanese male or female participants between the ages of 20 and 85 years, inclusive, at randomization.
- Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
- Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
- Capable of giving personal signed informed consent.
- Other medical or psychiatric condition including recent (within the past year) or
active suicidal ideation/behavior or laboratory abnormality that may increase the risk
of study participation or, in the investigator's judgment, make the participant
inappropriate for the study.
- Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
hepatitis B virus (HBV).
- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the study intervention(s).
- Receipt of medications intended to prevent COVID-19.
- Previous confirmed diagnosis of COVID-19.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined
by history and/or laboratory/physical examination.
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.
- Women who are pregnant or breastfeeding.
- Previous vaccination with any coronavirus vaccine.
- Individuals who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
planned receipt throughout the study.
- Receipt of blood/plasma products or immunoglobulin, from 60 days before study
intervention administration or planned receipt throughout the study.
- Participation in other studies involving study intervention within 28 days prior to
study entry and/or during study participation.
- Previous participation in other studies involving study intervention containing lipid
nanoparticles.
- Subset only: Any screening hematology and/or blood chemistry laboratory value that
meets the definition of a ≥ Grade 1 abnormality.
- Investigator site staff or Pfizer employees directly involved in the conduct of the
study, site staff otherwise supervised by the investigator, and their respective
family members.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anaheim, California
- Walnut Creek, California
- Hialeah, Florida
- Jacksonville, Florida
- Orlando, Florida
- Stockbridge, Georgia
- Honolulu, Hawaii
- Meridian, Idaho
- Bardstown, Kentucky
- Omaha, Nebraska
- Raritan, New Jersey
- Wilmington, North Carolina
- Salt Lake City, Utah
- Salt Lake City, Utah
- Oakland, California
- Milford, Connecticut
- Hialeah, Florida
- Hollywood, Florida
- Orlando, Florida
- Stockbridge, Georgia
- Honolulu, Hawaii
- Meridian, Idaho
- Bardstown, Kentucky
- Raritan, New Jersey
- Wilmington, North Carolina
- Cincinnati, Ohio
- Cincinnati, Ohio
- Houston, Texas
- San Antonio, Texas
- Tomball, Texas
- Salt Lake City, Utah
- Sumida-ku, Tokyo
- Fukuoka,
- Sumida-ku, Tokyo
- Fukuoka,